首页> 美国卫生研究院文献>other >A controversial step forward: a commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults
【2h】

A controversial step forward: a commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults

机译:向前迈出有争议的一步:2013年ACC / AHA血液胆固醇治疗指南的评论以减少成年人的动脉粥样硬化性心血管疾病风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 2013 ACC/AHA guidelines on the treatment of blood cholesterol in adults is a major step forward in the field of preventive cardiology but it is not without controversy. It should be well accepted that in individuals with established atherosclerotic vascular disease, individuals with a low-density lipoprotein cholesterol of greater than 190 mg/dl and individuals with diabetes, treatment with an appropriate fixed dose of a statin, without titration to a specific low-density lipoprotein goal, will provide substantial protection against future atherosclerotic vascular disease events. More controversial is the utilization of a risk calculator in primary care to determine which individuals will require a statin. For as long as these risk calculators are in question, primary care practitioners will struggle to make treatment decisions. Factors such as cardiovascular fitness, measures of adiposity, and details of the family history will aid in treatment decisions.
机译:2013年ACC / AHA关于成人血液胆固醇治疗的指南是预防性心脏病学领域迈出的重要一步,但这并非没有争议。应当很好地接受的是,对于已确诊的动脉粥样硬化性血管疾病的患者,低密度脂蛋白胆固醇大于190 mg / dl的患者和糖尿病患者,应使用适当的固定剂量的他汀类药物治疗,而无需滴定至特定的低剂量密度脂蛋白的目标,将为将来的动脉粥样硬化性血管疾病事件提供实质性的保护。更具争议的是在初级保健中使用风险计算器来确定哪些人将需要他汀类药物。只要这些风险计算器存在问题,初级保健医生就将难以做出治疗决策。诸如心血管健康,肥胖的测量方法和家族史的细节等因素将有助于治疗决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号